Author Archives: Yedida Y Bogachkov PhD

CAN10 Counters Scleroderma Development in Preclinical Study

Cantargia’s investigational antibody treatment, CAN10, showed promise in an animal model of systemic sclerosis (or scleroderma), normalizing several biological indicators of disease and counteracting disease development in the skin and lungs. “We are excited about these new results, showing strong effects of CAN10 in a systemic sclerosis model.

Rates of SSc, Raynaud’s Likely Higher Among Post-9/11 Veterans

A higher rate of systemic sclerosis (SSc), very early diagnosis of systemic sclerosis (VEDOSS), and Raynaud’s phenomenon is evident among U.S. military veterans deployed in support of post-9/11 operations, compared with the general population, a study suggests. The data, obtained through Veterans Health Administration (VHA) health records, highlight…

Scleroderma Outcomes Often Worse for Blacks, US Study Finds

Black patients with scleroderma are at higher risk of mortality and serious complications such as interstitial lung disease than those of other racial or ethnic groups, a single-center U.S. study found. These findings may foster early monitoring of these patients as well as greater awareness among clinicians, researchers…

FDA Grants Orphan Drug Status to Cudetaxestat

Cudetaxestat, a potential anti-scarring medication, has been granted orphan drug status by the U.S. Food and Drug Administration (FDA) for the treatment of scleroderma. “There are limited options and high medical need for patients suffering from systemic sclerosis [SSc, or scleroderma],” Daven Mody, vice president of regulatory affairs…